The PRPH2 and Associated Retinal Diseases (PARD) Science Award funds research on PRPH2-related retinal diseases, focusing on disease mechanisms and new therapies, from the Foundation Fighting Blindness.
Funder: Foundation Fighting Blindness
Due Dates (Anticipated): August 2026 (Letter of Intent) | November 2026 (Full Application)
Funding Amounts: Up to $500,000 total per award, for 1–3 years; no indirect costs or equipment allowed.
Summary: Supports innovative research into PRPH2-associated retinal diseases, with a focus on advancing understanding of disease mechanisms and developing therapeutic strategies.
Key Information: Letter of Intent required; eligibility is open internationally to faculty-level investigators.
This award, presented by the Foundation Fighting Blindness in partnership with the Nixon Visions Foundation, aims to accelerate scientific progress toward treatments for PRPH2-associated retinal diseases. The program funds meritorious research advancing the biology, pathophysiology, and therapeutic strategies for PRPH2-related inherited retinal degenerations. Areas of focus include fundamental PRPH2 biology, disease modeling, genotype-phenotype relationships, and proof-of-concept for therapies, particularly mutation-agnostic approaches. The ultimate goal is to foster discoveries that improve diagnoses, enable novel therapies, and enhance outcomes for affected individuals.